Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence
Source: ClinicalTrials.gov NCT03276780 ↗Summary
Linked Publications
-
Impact of Nicotine Replacement Therapy Sampling on Cessation-Related Processes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Participant Retention |
23; 29; 18; 10 | — |
| PRIMARY Rate of Recruitment |
5.84 | — |
| PRIMARY Rate of Enrollment |
1.43 | — |
| PRIMARY Treatment Satisfaction |
66.35; 65.62 | — |
| PRIMARY Treatment Satisfaction |
66.35; 65.62 | — |
| PRIMARY Treatment Satisfaction |
66.35; 65.62 | — |
| PRIMARY Treatment Expectancies at Baseline |
23.29; 21.23 | — |
| PRIMARY Treatment Credibility |
-0.26; -1.64 | — |
| PRIMARY Treatment Credibility |
-0.26; -1.64 | — |
| PRIMARY Treatment Credibility |
-0.26; -1.64 | — |
| PRIMARY Number of Participants With Medication Adherence at Week 6 |
22; 26; 23; 27 | — |
| PRIMARY Number of Participants With Medication Adherence at Week 9 |
23; 24; 26; 33 | — |
| PRIMARY Number of Participants With Medication Adherence at Week 13 |
18; 21; 17; 22 | — |
Eligibility Criteria
Inclusion Criteria
a) 18 years or older; b) qualifying as low income (as defined by making 50% African-American who average <10 CPD compared to Whites who average ~15 CPD.; and d) English speaking.
Exclusion Criteria
a) Living in a restricted environment (e.g., prison or jail facility, etc.); b) Pregnant or nursing (all women will be required to use an acceptable form of contraception); c) Currently enrolled in a smoking cessation treatment program, using NRT products, or prescribed bupropion or varenicline; d) Known allergy to any of the nicotine replacement products or sensitivity to adhesive used in nicotine patches; e) Trouble breathing, a pulmonary condition, or sinus problems; f) Within one month post-myocardial infarction or untreated severe angina; g) poor dentation or temporomandibular joint (TMJ) problems such as unable to use nicotine gum; h) Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included); or i) Daily or exclusive use of other tobacco products (e.g., electronic cigarettes, little cigars, etc.).
Data sourced from ClinicalTrials.gov (NCT03276780) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.